Related references
Note: Only part of the references are listed.Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs
Xiulong Shen et al.
NUCLEIC ACIDS RESEARCH (2018)
Chemokines in homeostasis and diseases
Keqiang Chen et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2018)
Effects of Mongersen (GED-0301) on Endoscopic and Clinical Outcomes in Patients With Active Crohn's Disease
Brian G. Feagan et al.
GASTROENTEROLOGY (2018)
Knockdown of Smad7 With a Specific Antisense Oligonucleotide Attenuates Colitis and Colitis-Driven Colonic Fibrosis in Mice
Roberta Izzo et al.
INFLAMMATORY BOWEL DISEASES (2018)
Chemical modifications of nucleic acid drugs and their delivery systems for gene-based therapy
Changmai Chen et al.
MEDICINAL RESEARCH REVIEWS (2018)
Phase 1 Clinical Study of siRNA Targeting Carbohydrate Sulphotransferase 15 in Crohn's Disease Patients with Active Mucosal Lesions
Kenji Suzuki et al.
JOURNAL OF CROHNS & COLITIS (2017)
Rectal Delivery of a DNAzyme That Specifically Blocks the Transcription Factor GATA3 and Reduces Colitis in Mice
Vanessa Popp et al.
GASTROENTEROLOGY (2017)
Novel Insights into the Mechanisms of Gut Homing and Antiadhesion Therapies in Inflammatory Bowel Diseases
Sebastian Zundler et al.
INFLAMMATORY BOWEL DISEASES (2017)
Enhancing the Therapeutic Delivery of Oligonucleotides by Chemical Modification and Nanoparticle Encapsulation
Yating Sun et al.
MOLECULES (2017)
The chemical evolution of oligonucleotide therapies of clinical utility
Anastasia Khvorova et al.
NATURE BIOTECHNOLOGY (2017)
Current and emerging therapeutic targets for IBD
Markus F. Neurath
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2017)
Crystal structure of an RNA-cleaving DNAzyme
Hehua Liu et al.
NATURE COMMUNICATIONS (2017)
Advances in the delivery of RNA therapeutics: from concept to clinical reality
James C. Kaczmarek et al.
GENOME MEDICINE (2017)
Ameliorating Active Ulcerative Colitis via an Orally Available Toll-Like Receptor-9 Modifier: A Prospective Open-Label, Multicenter Phase II Trial
Iris Dotan et al.
DIGESTIVE DISEASES AND SCIENCES (2016)
RNA cleavage products generated by antisense oligonucleotides and siRNAs are processed by the RNA surveillance machinery
Walt F. Lima et al.
NUCLEIC ACIDS RESEARCH (2016)
Pivotal Role of Carbohydrate Sulfotransferase 15 in Fibrosis and Mucosal Healing in Mouse Colitis
Kenji Suzuki et al.
PLOS ONE (2016)
Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides
Richard S. Geary et al.
ADVANCED DRUG DELIVERY REVIEWS (2015)
An orally administrated nucleotide-delivery vehicle targeting colonic macrophages for the treatment of inflammatory bowel disease
Zhen Huang et al.
BIOMATERIALS (2015)
Pathogenic aspects and therapeutic avenues of intestinal fibrosis in Crohn's disease
Francesca Zorzi et al.
CLINICAL SCIENCE (2015)
Molecular interactions between chondroitin-dermatan sulfate and growth factors/receptors/matrix proteins
Shuji Mizumoto et al.
CURRENT OPINION IN STRUCTURAL BIOLOGY (2015)
Mongersen, an Oral SMAD7 Antisense Oligonucleotide, and Crohn's Disease
Giovanni Monteleone et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Biomarkers can predict potential clinical responders to DIMS0150 a toll-like receptor 9 agonist in ulcerative colitis patients
Nikolai V. Kuznetsov et al.
BMC GASTROENTEROLOGY (2014)
Overexpression of GATA-3 in T Cells Accelerates Dextran Sulfate Sodium-Induced Colitis
Midori Okamura et al.
EXPERIMENTAL ANIMALS (2014)
GATA-3 Function in Innate and Adaptive Immunity
Irma Tindemans et al.
IMMUNITY (2014)
Phosphorothioates, Essential Components of Therapeutic Oligonucleotides
Fritz Eckstein
NUCLEIC ACID THERAPEUTICS (2014)
Crohn's disease complicated by strictures: a systematic review
Florian Rieder et al.
GUT (2013)
Topical Treatment with the Toll-like Receptor Agonist DIMS0150 Has Potential for Lasting Relief of Symptoms in Patients with Chronic Active Ulcerative Colitis by Restoring Glucocorticoid Sensitivity
Eugen Musch et al.
INFLAMMATORY BOWEL DISEASES (2013)
A phase 1 open-label trial shows that smad7 antisense oligonucleotide (GED0301) does not increase the risk of small bowel strictures in Crohn's disease
F. Zorzi et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2012)
Molecular function of macrophage migration inhibitory factor and a novel therapy for inflammatory bowel disease
Jun Nishihira
NUTRITION AND PHYSICAL ACTIVITY IN AGING, OBESITY, AND CANCER (2012)
Phase I Clinical Trial of Smad7 Knockdown Using Antisense Oligonucleotide in Patients With Active Crohn's Disease
Giovanni Monteleone et al.
MOLECULAR THERAPY (2012)
A New Therapeutic Approach Using a Schizophyllan-based Drug Delivery System for Inflammatory Bowel Disease
Hidetoshi Takedatsu et al.
MOLECULAR THERAPY (2012)
Oral nuclear factor-kappa B decoy oligonucleotides delivery system with chitosan modified poly(D,L-lactide-co-glycolide) nanospheres for inflammatory bowel disease
Kohei Tahara et al.
BIOMATERIALS (2011)
Transcript levels of Toll-Like receptors 5, 8 and 9 correlate with inflammatory activity in Ulcerative Colitis
Fausto Sanchez-Munoz et al.
BMC GASTROENTEROLOGY (2011)
An Overview of Sugar-Modified Oligonucleotides for Antisense Therapeutics
Thazha P. Prakash
CHEMISTRY & BIODIVERSITY (2011)
Regulation of Homeostasis and Inflammation in the Intestine
Thomas T. MacDonald et al.
GASTROENTEROLOGY (2011)
Toll-like Receptors and Their Crosstalk with Other Innate Receptors in Infection and Immunity
Taro Kawai et al.
IMMUNITY (2011)
Long-term Complications, Extraintestinal Manifestations, and Mortality in Adult Crohn's Disease in Population-Based Cohorts
Laurent Peyrin-Biroulet et al.
INFLAMMATORY BOWEL DISEASES (2011)
Intestinal homeostasis and its breakdown in inflammatory bowel disease
Kevin J. Maloy et al.
NATURE (2011)
Inflammation meets cancer, with NF-κB as the matchmaker
Yinon Ben-Neriah et al.
NATURE IMMUNOLOGY (2011)
Mechanisms of single-stranded phosphorothioate modified antisense oligonucleotide accumulation in hepatocytes
Erich Koller et al.
NUCLEIC ACIDS RESEARCH (2011)
Targeting delivery of anti-TNF alpha oligonucleotide into activated colonic macrophages protects against experimental colitis
Longsheng Zuo et al.
GUT (2010)
T cell-dependent protective effects of CpG motifs of bacterial DNA in experimental colitis are mediated by CD11c+ dendritic cells
Claudia Hofmann et al.
GUT (2010)
Homing of Immune Cells: Role in Homeostasis and Intestinal Inflammation
Ailsa L. Hart et al.
INFLAMMATORY BOWEL DISEASES (2010)
G3139, an Anti-Bcl-2 Antisense Oligomer That Binds Heparin-Binding Growth Factors and Collagen I, Alters In vitro Endothelial Cell Growth and Tubular Morphogenesis
C. A. Stein et al.
CLINICAL CANCER RESEARCH (2009)
The Effects of Cytokines on Suppression of Lymphocyte Proliferation by Dexamethasone
Tom J. Creed et al.
JOURNAL OF IMMUNOLOGY (2009)
MECHANISMS OF DISEASE Inflammatory Bowel Disease
Clara Abraham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Unravelling the pathogenesis of inflammatory bowel disease
R. J. Xavier et al.
NATURE (2007)
Inhibition of Smad7 with a specific antisense oligonucleotide facilitates TGF-β1-mediated suppression of colitis
Monica Boirivant et al.
GASTROENTEROLOGY (2006)
Antisense therapy of MAdCAM-1 for trinitrobenzenesulfonic acid-induced murine colitis
Akira Goto et al.
INFLAMMATORY BOWEL DISEASES (2006)
A Phase II dose ranging, double-blind, placebo-controlled study of alicaforsen enema in subjects with acute exacerbation of mild to moderate left-sided ulcerative colitis
SJH Van Deventer et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2006)
Safety and efficacy of two dose formulations of alicaforsen enema compared with mesalazine enema for treatment of mild to moderate left-sided ulcerative colitis: a randomized, double-blind, active-controlled trial
PB Miner et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2006)
Bioavailability and therapeutic activity of alicaforsen (ISIS 2302) administered as a rectal retention enema to subjects with active ulcerative colitis
PB Miner
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2006)
Expression of Toll-like receptor 9 and response to bacterial CpG oligodeoxynucleotides in human intestinal epithelium
G Pedersen et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2005)
Biochemical and immunohistochemical analysis of glycosaminoglycans in inflamed and non-inflamed intestinal mucosa of patients with Crohn's disease
CLR Belmiro et al.
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE (2005)
CD40 antisense oligonucleotide inhibition of trinitrobenzene sulphonic acid induced rat colitis
D Gao et al.
GUT (2005)
TGF-β signaling and the fibrotic response
A Leask et al.
FASEB JOURNAL (2004)
An enema formulation of alicaforsen, an antisense inhibitor of intercellular adhesion molecule-1, in the treatment of chronic, unremitting pouchitis
P Miner et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2004)
A randomised, controlled, double blind, escalating dose study of alicaforsen enema in active ulcerative colitis
SJH van Deventer et al.
GUT (2004)
The immunological and genetic basis of inflammatory bowel disease
G Bouma et al.
NATURE REVIEWS IMMUNOLOGY (2003)
Mechanisms of TGF-β signaling from cell membrane to the nucleus
YG Shi et al.
CELL (2003)
Leukocyte-endothelial-cell interactions in leukocyte transmigration and the inflammatory response
WA Muller
TRENDS IN IMMUNOLOGY (2003)
Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease
F Baert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Antisense oligonucleotide blockade of tumor necrosis factor-alpha in two murine models of colitis
KJ Myers et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2003)
A murine model of chronic inflammation-induced intestinal fibrosis down-regulated by antisense NF-kappa B
IC Lawrance et al.
GASTROENTEROLOGY (2003)
Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease
BR Yacyshyn et al.
GUT (2002)
Transforming growth factor-beta in T-cell biology
L Gorelik et al.
NATURE REVIEWS IMMUNOLOGY (2002)
Development of chronic colitis is dependent on the cytokine MIF
YP de Jong et al.
NATURE IMMUNOLOGY (2001)
Absence of efficacy of subcutaneous antisense ICAM-1 treatment of chronic active Crohn's disease
S Schreiber et al.
GASTROENTEROLOGY (2001)
Macrophage migration inhibitory factor in the sera and at the colonic mucosa in patients with ulcerative colitis: clinical implications and pathogenic significance
H Murakami et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2001)
A Toll-like receptor recognizes bacterial DNA
H Hemmi et al.
NATURE (2000)
Changed colonic profile of P-selectin, platelet-endothelial cell adhesion molecule-1 (PECAM-1), intercellular adhesion molecule-1 (ICAM-1), ICAM-2, and ICAM-3 in inflammatory bowel disease
B Vainer et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2000)
Treatment of experimental (Trinitrobenzene sulfonic acid) colitis by intranasal administration of transforming growth factor (TGF)-β1 plasmid:: TGF-β1-mediated suppression of T helper cell type 1 response occurs by interleukin (IL)-10 induction and IL-12 receptor β2 chain downregulation
A Kitani et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
Therapeutic effect of intracolonically administered nuclear factor κB (p65) antisense oligonucleotide on mouse dextran sulphate sodium (DSS)-induced colitis
M Murano et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2000)
Phosphorothioate oligodeoxynucleotides: What is their origin and what is unique about them?
F Eckstein
ANTISENSE & NUCLEIC ACID DRUG DEVELOPMENT (2000)
Nucleocytoplasmic shuttling:: a novel in vivo property of antisense phosphorothioate oligodeoxynucleotides
P Lorenz et al.
NUCLEIC ACIDS RESEARCH (2000)
Intercellular adhesion molecule-1 (ICAM-1) deficiency protects mice against severe forms of experimentally induced colitis
F Bendjelloul et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2000)
Share Paper
